FDA approval of retinal dystrophy drug launches era of ocular gene therapy – ModernMedicine
FDA approval of retinal dystrophy drug launches era of ocular gene therapyModernMedicineIn December 2017, the FDA approved voretigene neparvovec-rzyl (“voretigene,” Luxturna, Spark Therapeutics), an adeno-associated virus serotype 2 vector-based gene t… Continue reading
